Hundreds of researchers, medical professionals and industry leaders gathered together in Washington, D.C. Wednesday for a summit on the “cancer moonshot,” a program spearheaded by Vice President Joe Biden with ties to critical innovations happening at UC Berkeley.
The cancer moonshot, which was established by President Barack Obama during his final State of the Union Address, aims to end cancer as it is known today. One of the key discoveries in that effort is CRISPR/Cas9 , a gene-editing technique pioneered by Jennifer Doudna, a UC Berkeley professor of molecular and cell biology and of chemistry and a Howard Hughes Medical Institute investigator. CRISPR/Cas9 allows for fast, precise editing of very small portions of the genome.
Doudna met with Biden during January’s World Economic Forum in Davos, Switzerland, to discuss how the technology could be used to combat various forms of cancer.
“We can harness the power of the human genome to understand disease,” Doudna tweeted at the time.